Transgene

Beleggen in aandelenbeurzen Europa: DAX, FTSE 100, CAC40, etc.

Beleggen met ongekend lage tarieven?
Aandelen BE/NL €2+0,03% / VS €0,50+$0,004 p/st
Kernselectie: Geen kosten turbo's, ETF's en fondsen
DEGIRO: meer informatie / rekening openen


Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

Blok van 100.000 stukjes op de 1.75€ :wtf:







Volg Beursig.com op Twitter en Facebook


Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

Geplukt van het Boursorama forum

Orginele bron:
https://www.medesispharma.com/preclinic ... transgene/
TRANSGENE (Euronext Paris: TNG), a biotechnology company designing and developing virus-based immunotherapies against cancers and infectious diseases, has signed a collaborative research agreement with Medesis Pharma with exclusive license options to co-develop an intracellular protein inhibitor that decreases the efficacy of oncolytic viruses.

Medesis Pharma handled the siRNA design, synthesis and formulation in the Aonys® microemulsion. TRANSGENE carried out a first pharmacologic study, enabling it to validate the target gene inhibition and the resulting optimization of the efficacy of its oncolytic viruses.
Opmerkelijk dat Transgene hierover zelf geen pb publiceert.
Medesis Pharma, a pharmaceutical biotechnology company developing drug candidates with its proprietary technology for administering active ingredients in nanomicelles by the oral route, announces the renewal of its collaborative research agreement with Transgene, a biotechnology company that designs and develops immunotherapies from the cancer based on viral vectors.
Initially signed in July 2019, and after a first phase of conclusive research, the collaborative research agreement with Transgene is renewed for a period of 6 months. It aims to apply Medesis Pharma's proprietary technology, Aonys, to the optimization of the treatment of tumors with oncolytic viruses. This collaboration makes it possible to test an innovative approach for modulating the tumor microenvironment, in order to increase the therapeutic efficacy of oncolytic viruses.
Medesis Pharma carries out the design, synthesis and formulation of these oligonucleotides in the Aonys microemulsion. Transgene finances this work and conducts pharmacological and mechanistic studies. The first preclinical results obtained are very encouraging and make it possible to envisage a future therapeutic application in association with oncolytic viruses.
Our own advanced clinical research programs on major diseases
This collaborative project with Transgene is part of Medesis Pharma's collaborative research programs.
In its own right, Medesis Pharma is more particularly dedicated to the development of drug candidates for major diseases, without any effective treatment. Choices of proven active ingredients and delivery revolutionized by Aonys resulted in the implementation of four programs that come into clinical Phase II in 2021:
. 2 drug candidates in the field of neurodegenerative diseases to treat Alzheimer's disease and Huntington's disease,
. 2 drug candidates to treat severe respiratory inflammation that Medesis Pharma in the face of the health emergency, has focused on the treatment of COVID-19, one for severe cases and a specific antiviral intended for city medicine at the start of the disease.
“The renewal of our agreement with Transgene demonstrates the value of our Aonys technology, the result of many years of research. The easy oral administration of a stable microemulsion brings about considerable medical advantages which are reflected in particular in a protected and invisible transport in the organism of the pharmaceutical active ingredient, an internalization in all the cells. Beyond the potential of collaborative research programs in oncology, our 4 drug candidates for neurodegenerative diseases and COVID-19 have the potential to provide unprecedented solutions to the diseases of our century ”declares Jean Claude Maurel, President and founder by Medesis Pharma.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene Appoints Hedi Ben Brahim As Chairman And CEO
18:01 (03/12) - Bron: Reuters
Dec 3 (Reuters) - Transgene SA :
* TRANSGENE APPOINTS HEDI BEN BRAHIM AS CHAIRMAN AND CHIEF
EXECUTIVE OFFICER
* APPOINTMENT OF HEDI BEN BRAHIM AS COMPANY'S NEW CHAIRMAN
AND
CEO, EFFECTIVE JANUARY 1ST, 2021

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
de vorige heeft het goed gedaan :lol: -90% op 10 jaar.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

Transgene to present Phase 1b/2 trial results
of TG4001 in combination with avelumab
in advanced HPV-positive cancers at ESMO IO 2020

Strasbourg, France, December 3, 2020, 06:45 pm CET – Transgene (Euronext Paris: TNG), a biotech
company that designs and develops virus-based immunotherapeutics against cancer, will present the
Phase 1b/2 trial results of TG4001, a HPV16 targeted therapeutic vaccine, in combination with avelumab
(BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies at
ESMO Immuno-Oncology Virtual Congress 2020, December 9-12, 2020.
These data will be presented by the principal investigator, Professor Christophe Le Tourneau, M.D., PhD,
Head of the Department of Drug Development and Innovation (D3i) at the Institut Curie (Paris) in an oral
presentation on December 12, 2020 at 12:40 pm CET.
Professor Christophe Le Tourneau added: “Current treatments for HPV-16 positive cancer patients do not
address the viral origin of the disease. These data are a very encouraging first step to hopefully provide
patients with better treatment options, particularly for patients with advanced disease who have a
devastating disease with poor prognosis.”
Number and title of the abstract and mini-oral presentation: (abstract #276, presentation #63 MO)
TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor
microenvironment (TME) and drives antitumor responses in Human PapillomaVirus (HPV)+ malignancies
Authors: Christophe Le Tourneau, Philippe Cassier, Frédéric Rolland, Sébastien Salas, Jean-Marc Limacher,
Olivier Capitain, Olivier Lantz, Ana Lalanne, Christina Ekwegbara, Annette Tavernaro, Hakim Makhloufi,
Kaïdre Bendjama, Jean-Pierre Delord.
Session date and time: Mini Oral Session 2, December 12, 2020, 12:35-1:55 pm CET (Channel 1). The
session consists of short oral presentations by authors, followed by expert discussion and perspectives.
Key results of the trial (n=34 evaluable patients):
- The combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity
(23.5% ORR) in patients with previously treated recurrent and/or metastatic HPV-related cancers.

- The presence of liver metastases has a notable impact on outcome in terms of ORR and PFS. In
patients without liver metastases, an ORR of 34.8% and a median PFS of 5.6 months were achieved.
- The disease control rate (DCR) at 12 weeks was 56.6% in patients without liver metastasis, against
9.1% in patients with liver metastasis.
- The treatment induced HPV-specific T-cell responses and was associated with increased levels of
immune cell infiltration in the tumors and expression of genes associated with activation of the
immune system.
- These results warrant further confirmation in a larger controlled randomized study.
NewB76 liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene And Bioinvent Receive CTA Approval For Phase 1/2A Trial Of Oncolytic Virus BT-001 In Solid Tumors
08:34 (21/12) - Bron: Reuters
Dec 21 (Reuters) - Transgene :
* TRANSGENE AND BIOINVENT RECEIVE CTA APPROVAL FOR PHASE
1/2A
TRIAL OF ONCOLYTIC VIRUS BT-001 IN SOLID TUMORS

Source text for Eikon:
Further company coverage: ,

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
NewB76 liked last!

mongoose
Forum actieveling
Forum actieveling
Berichten: 316
Lid geworden op: 22 nov 2016 15:01
waarderingen: 182
Contacteer:

Re: Transgene

Bericht door mongoose »

And its gone! liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

mongoose schreef:
07 jan 2021 20:02
Nieuwe presentatie

https://www.transgene.fr/wp-content/upl ... tation.pdf
Ze hebben er eens werk van gemaakt.

Uitkijken naar BT en of Astrazeneca toehapt, dan kan het wel eens interessant worden. Maar waarschijnlijk niet, haha.

mongoose
Forum actieveling
Forum actieveling
Berichten: 316
Lid geworden op: 22 nov 2016 15:01
waarderingen: 182
Contacteer:

Re: Transgene

Bericht door mongoose »

Nu gaat de koers toch wel richting hoogste jaarkoers. Allez, anderhalf jaar. Na hun stevige duik in augustus 2019, gingen ze nog maanden bergaf. Intussen toch wel wat meer opwaarts.
And its gone! liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

5x dagelijks volume.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 908
Lid geworden op: 30 mei 2018 21:25
waarderingen: 419
Contacteer:

Re: Transgene

Bericht door And its gone! »

rustige stijging, maar de trend zet zich door.
Na een half uur zitten we al aan het dagelijks gemiddeld volume!
Zien we de 2€ vandaag? :up:


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie